Prothena (PRTA) to Release Earnings on Thursday

Prothena (NASDAQ:PRTA – Get Rating) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 5th. Analysts expect Prothena to post earnings of ($0.85) per share for the quarter. Prothena has set its Q4 guidance at ($0.71) EPS.

Prothena (NASDAQ:PRTA – Get Rating) last posted its quarterly earnings data on Thursday, February 17th. The biotechnology company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.03. The company had revenue of $1.17 million during the quarter, compared to analysts’ expectations of $0.28 million. Prothena had a return on equity of 18.11% and a net margin of 33.39%. During the same period in the prior year, the firm earned ($0.77) earnings per share. On average, analysts expect Prothena to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

PRTA stock opened at $29.98 on Friday. The stock has a market capitalization of $1.40 billion, a P/E ratio of 27.50 and a beta of 1.30. The business has a 50-day moving average of $34.99 and a 200-day moving average of $43.06. Prothena has a fifty-two week low of $21.30 and a fifty-two week high of $79.75.

Several research analysts have recently weighed in on the company. Citigroup reduced their price objective on Prothena from $87.00 to $73.00 in a research report on Friday, February 18th. StockNews.com initiated coverage on Prothena in a report on Thursday, March 31st. They set a “hold” rating on the stock. Finally, Zacks Investment Research upgraded Prothena from a “sell” rating to a “hold” rating and set a $35.00 target price on the stock in a report on Wednesday, April 20th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $64.73.

In other news, Director Shane Cooke sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, April 11th. The stock was sold at an average price of $35.08, for a total value of $175,400.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 31.20% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Norges Bank acquired a new stake in Prothena during the fourth quarter worth approximately $3,794,000. BlackRock Inc. boosted its holdings in shares of Prothena by 2.7% in the 4th quarter. BlackRock Inc. now owns 3,872,300 shares of the biotechnology company’s stock valued at $191,292,000 after purchasing an additional 102,596 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Prothena by 182.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,116 shares of the biotechnology company’s stock valued at $10,577,000 after purchasing an additional 138,207 shares in the last quarter. Allianz Asset Management GmbH acquired a new stake in shares of Prothena in the 4th quarter valued at $815,000. Finally, California State Teachers Retirement System boosted its holdings in shares of Prothena by 5.1% in the 4th quarter. California State Teachers Retirement System now owns 46,432 shares of the biotechnology company’s stock valued at $2,294,000 after purchasing an additional 2,241 shares in the last quarter. 89.45% of the stock is currently owned by institutional investors and hedge funds.

Prothena Company Profile (Get Rating)

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.

See Also